Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal shows - once again - that all is not lost when Big Pharma hands back a product

You may also be interested in...

Vasopharm Raises $6.5 mill For Phase III-Ready Traumatic Brain Injury Therapy

The tiny German biotech, vasopharm, aims to maximize the attractiveness of its NO-synthase inhibitor for potential partners, and to keep the flag flying for nitric oxide research.

Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University

This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.

NicOx Kicks Off Specialty Ophthalmics Transformation With Altacor Buy

France's NicOx, aiming to transform into a specialty ophthalmology company after several late-stage disappointments, announced plans to acquire VC-backed U.K startup Altacor.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts